NYSE:LLY
Eli Lilly & Co. (LLY)
Financials 
Technical Analysis 
Aug 5, 2026, 12:00 amThis summary was created by AI, based on 29 opinions in the last 12 months.
Eli Lilly & Co. (LLY) is positioning itself strongly in the healthcare market, particularly in the GLP-1 drug sector, leading to significant earnings growth expectations of around 25% annually in the coming years. Analysts emphasize LLY's competitive edge over Novo Nordisk (NVO), noting that their innovations have resulted in increased market share, particularly with the anticipated approval of an oral weight-loss pill. Many highlights include a solid pipeline of drugs and an expanding presence in treatment areas such as obesity and diabetes, while recent momentum has seen the stock breaking into new highs. However, there's caution over potential valuations due to the stock’s strong performance and the RSI nearing overbought territory. Overall, LLY is seen as a reliable long-term growth story amid a transformation from a traditional steady income earner to a fast-growing pharmaceutical company.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Better product than NVO. So he'd be buying this one (but not at today's price ;)
Greg Newman
Clear leader in diabetes and weight loss. Other players are coming in, but this name is ahead of the curve. Very strong earnings growth over next few years (50% for 2026, 22% for 2027, 17% for 2028). Reliable aspects of a pharmaceutical healthcare name, plus very strong earnings growth.
RSI is 70, so wait for a bit of a pullback.
Stan WongLargest pharma company in the US, and possibly the world. Breaking out to fresh all-time highs. Leading GLP-1 drugs. 150-year history of healthcare innovation.
Obesity + diabetes comprise ~55% of revenues, and growing fast. Also into oncology, immunology, neuroscience, and more. Well-insulated from patent cliffs. 80% of marketed drugs are "biologic", which stand up better to generic competition. Prolific FCF. M&A frenzy this year on top of pretty robust R&D. Yield is 0.61% (growing 15% compound pace over last 5 years, should continue).
Brian MaddenHas owned a long time in the growth fund. It is a leader in GLP 1. Every year the weight loss drugs seem to be able to treat another condition so it is a bit of a miracle drug. Is still early for these drugs. It is expensive so if you want something else you could try Thermo Fisher for broad exposure. The health care sector still has an overhang from Covid and the US government has pulled back on spending.
Jamie Murray What we're seeing now are expectations settling after a very strong runup. Still at the centre of the biggest shift in healthcare. Keeps expanding its opportunities and taking market share.
Brianne GardnerWinning the weight-loss drug war. Active pipeline.
Bruce Murray
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Popular Articles
Eli Lilly & Co. (LLY) Frequently Asked Questions
What is Eli Lilly & Co. stock symbol?
Eli Lilly & Co. is a American stock, trading under the symbol LLY (previously LLY-N on Stockchase) on the New York Stock Exchange (LLY). It is usually referred to as NYSE:LLY or LLY
Is Eli Lilly & Co. a buy or a sell?
In the last year, 26 stock analysts issued a Buy, Sell, or Hold rating on LLY (previously LLY-N on Stockchase). 21 analysts recommended to BUY and 1 analyst recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Eli Lilly & Co..
Is Eli Lilly & Co. a good investment or a top pick?
Eli Lilly & Co. was recommended as a Top Pick by Stan Wong on 2026-07-09. Read the latest stock experts ratings for Eli Lilly & Co..
Why is Eli Lilly & Co. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Eli Lilly & Co..
Is Eli Lilly & Co. worth watching?
Eli Lilly & Co. is followed by 220 investors on Stockchase and is a trending stock that is worth watching.
What is Eli Lilly & Co. stock price?
On 2026-08-05, Eli Lilly & Co. (LLY) stock closed at a price of $1,157.05.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999944)'%3e%3cg%20id='Group-8'%20transform='translate(90.000000,%200.000000)'%3e%3cpath%20d='M11.4997292,5.58581788e-05%20C12.2854126,-0.00429698998%2013.2541635,0.496661868%2013.6456551,1.25176162%20L13.7121092,1.39625969%20L15.7478626,6.4533458%20L21.0287785,6.8043135%20C21.60867,6.84285288%2022.1472423,7.12366313%2022.5172746,7.58041175%20C23.2234049,8.45202216%2023.142035,9.7221751%2022.3571045,10.4940309%20L22.2340987,10.60596%20L18.0726557,14.1089676%20L19.3563392,19.5925566%20C19.4721567,20.0873014%2019.3941255,20.6085828%2019.1388305,21.0456062%20C18.6243292,21.9263484%2017.5369557,22.2447761%2016.6497127,21.8011012%20L16.5113976,21.7246849%20L11.5,18.7716134%20L6.48860242,21.7246849%20C5.5790916,22.2767372%204.40274983,21.9727033%203.86116953,21.0456062%20C3.60587449,20.6085828%203.52784326,20.0873014%203.64366079,19.5925566%20L4.9273443,14.1089676%20L0.76590125,10.60596%20C-0.13192926,9.85018675%20-0.258711404,8.49560268%200.482725407,7.58041175%20C0.85275775,7.12366313%201.39132997,6.84285288%201.97122149,6.8043135%20L7.25213737,6.4533458%20L9.28789079,1.39625969%20C9.62402537,0.561256055%2010.6655161,-0.00457632221%2011.4997292,5.58581788e-05%20Z'%20id='top-picks-.-icon-copy-7'%20fill='%23FFB800'%3e%3c/path%3e%3cpath%20d='M11.4997292,2.77818228e-05%20C12.2854126,-0.00429698998%2013.2541635,0.496661868%2013.6456551,1.25176162%20L13.7121092,1.39625969%20L15.7478626,6.4533458%20L21.0287785,6.8043135%20C21.60867,6.84285288%2022.1472423,7.12366313%2022.5172746,7.58041175%20C23.2234049,8.45202216%2023.142035,9.7221751%2022.3571045,10.4940309%20L22.2340987,10.60596%20L18.0726557,14.1089676%20L19.3563392,19.5925566%20C19.4721567,20.0873014%2019.3941255,20.6085828%2019.1388305,21.0456062%20C18.6243292,21.9263484%2017.5369557,22.2447761%2016.6497127,21.8011012%20L16.5113976,21.7246849%20L11.5,18.7716134%20C11.4998195,6.25722299%2011.4997292,2.77818228e-05%2011.4997292,2.77818228e-05%20Z'%20id='top-picks-.-icon-copy-8'%20fill='%23EAEAEA'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Broad pipeline, but its leadership in GLP-1 is what's really pushing the stock. New catalyst is approval for oral pill. Winning battle against NVO. Sees ~25% earnings growth rate over next several years.
(Analysts’ price target is $1257.50)Broken out to a new space on the charts. He looks to buy on dips if possible. Yield is 0.57%.